Pharmacokinetics and pharmacodynamics of insulin detemir (Levemir®) and insulin glargine (Lantus®) after subcutaneous injection of increasing doses into morbidly obese type 2 diabetic subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN57547229

Enrollment

Registered

2006-05-09

Start date

2006-04-20

Completion date

Unknown

Last updated

2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, obesity Nutritional, Metabolic, Endocrine Diabetes and obesity

Interventions

Application of insulin determir (Levemir) versus insulin glargine (Lantus)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. History of type 2 diabetes mellitus 2. Age 18-65 years 3. Body mass index >35 kg/m^2 4. HbA1c <10%

Exclusion criteria

Exclusion criteria: 1. Any severely active hepatic, cardiovascular, pulmonary, renal, neurological, musculoskeletal, hematological or endocrine disease 2. Pregnant or breast feeding women 3. Woman of childbearing potential not using a reliable method of birth control such as oral contraceptives or an intrauterine device (IUD) 4. Subjects refusing or unable to give written informed consent

Design outcomes

Primary

Measure	Time frame
Pharmacodynamics of the two insulins (detemir and glargine)	—

Secondary

Measure	Time frame
1. Pharmacokinetics of the two insulins (detemir and glargine) 2. Correlation pharmacodynamics and (central) obesity	—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 23, 2026